Liposomal borrelidin for treatment of metastatic breast cancer

Cited 0 time in webofscience Cited 0 time in scopus
  • Hit : 118
  • Download : 0
Borrelidin is an inhibitor of threonyl-tRNA synthetase with both anticancer and antiangiogenic activities. Although borrelidin could be a potent drug that can treat metastatic cancer through synergistic therapeutic effects, its severe liver toxicity has limited the use for cancer therapeutics. In this study, we developed a liposomal formulation of borrelidin to treat metastatic breast cancer effectively through its combined anticancer and antiangiogenic effects while reducing the potential liver toxicity. The liposomal formulation was optimized to maximize loading stability and efficiency of lipophilic borrelidin in the liposomal membrane and its delivery efficiency to primary tumor in a mouse model of metastatic breast cancer. Liposomal borrelidin showed significant in vitro therapeutic effects on proliferation and migration of tumor cells and angiogenesis of endothelial cells. Furthermore. liposomal borrelidin exhibited superior inhibitory effects on primary tumor growth and lung metastasis in vivo compared to free borrelidin. More importantly, liposomal borrelidin did not induce any significant systemic toxicity in the mouse model after multiple injections.
Publisher
SPRINGER HEIDELBERG
Issue Date
2018-10
Language
English
Article Type
Article
Keywords

TRANSFER-RNA SYNTHETASE; DRUG-DELIVERY; CELL-MIGRATION; IN-VITRO; MODEL; ANGIOGENESIS; DOXORUBICIN; THERAPEUTICS; CHEMOTHERAPY; SUPPRESSION

Citation

DRUG DELIVERY AND TRANSLATIONAL RESEARCH, v.8, no.5, pp.1380 - 1388

ISSN
2190-393X
DOI
10.1007/s13346-018-0563-z
URI
http://hdl.handle.net/10203/245876
Appears in Collection
BiS-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0